Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions

Journal of Pharmaceutical Sciences

Volumn 101, Issue 1, 2012, Pages 21-30

  Sreedhara, Alavattam ^a   Glover, Zephania Kwong ^a   Piros, Nicole ^a   Xiao, Nina ^a   Patel, Ankit ^a   Kabakoff, Bruce ^a  

^a GENENTECH INC   (United States)

Author keywords

Beyond use dating; Chemical stability; Compounded sterile preparation (CSP); Infusion bags; Monoclonal antibodies; Physical stability; Protein formulation; Proteins; Stability; USP 797

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY;

ARTICLE; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRUG USE; HUMAN; MEDICAL LITERATURE; PHARMACEUTICS; PHARMACIST; UNITED STATES;

EID: 82255174941     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22739     Document Type: Article

References (22)

1. Vigneron J. 2006. Stability studies of drugs used in oncology: The role of the hospital pharmacist. Eur J Hosp Pharm Sci 12:75-76.
2. Kienle PC. 2007. Understanding beyond-use dating for compounded sterile preparations. Pharm Purch Prod 4(3):2-5.
3. USP. 2008. General information Chapter 797: Pharmaceutical compounding-Sterile preparations. Second supplement to the United States Pharmacopeia, 26th ed, pp 3700-3734.
4. Ikesue H, Vermeulen LC, Hoke R, Kolesar JM. 2010. Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags. Am J Health Syst Pharm 67:223-226.
5. Kupfer M, Scriba G, Hartmann M. 2009. Stability of alemtuzumab in infusion-bags. Pharmazie 64(9):622-623.
6. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96(1):1-26.
7. Fischer S, Hoernschemeyer J, Mahler HC. 2008. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm 70(1):42-50.
8. Kerwin BA. 2008. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. J Pharm Sci 97(8):2924-2935.
9. Demeule B, Messick S, Shire SJ, Liu J. 2010. Characterization of particles in protein solutions: Reaching the limits of current technologies. AAPS J 12(4):708-715.
10. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98(4):1201-1205.
11. USP. 2004. Chapter 788: Particulate matter in injections. United States Pharmacopeia, 27th revision, pp 2338-2344.
12. Wang W, Nema S, Teagarden D. 2010. Protein aggregation-Pathways and influencing factors. Int J Pharm 390(2):89-99.
13. Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98(9):2909-2934.
14. Kiese S, Papppenberger A, Friess W, Mahler HC. 2008. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97(10):4347-4366.
15. Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, Forrest DL, Gagnon RF, Harvey EA, Laneuville P, Patterson BJ, Poon MC, Posen GA, Messner HA, Canadian PRCA Focus Group. 2004. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk. J Am Soc Nephrol 15(10):2728-2734.
16. Deechongkit S, Wen J, Narhi LO, Jiang Y, Park SS, Kim J, Kerwin BA. 2009. Physical and biophysical effects of Polysorbate 20 and 80 on darbepoetin alfa. J Pharm Sci 98(9):3200-3217.
17. Cao S, Jiang Y, Narhi L. 2010. A Light-obscuration method specific for quantifying subvisible particles in protein therapeutics. Pharmacopeial Forum 36(3), 824-34.
18. Astier A. 2007. The stability of anticancer drugs. Eur J Oncol Pharm 1:21-23.
19. Deonarain MP. 2008. Recombinant antibodies for cancer therapy. Expert Opin Biol Ther 8(8):1123-1141.
20. Bakshi M, Singh S. 2002. Development of validated stability-indicating assay methods-Critical review. J Pharm Biomed Anal 28(6):1011-1040.
21. Chang JY, Xiao NJ, Zhu M, Zhang Z, Hoff E, Russell SJ, Katta V, Shire SJ. 2010. Leachables from saline-containing IV bags can alter therapeutic protein properties. Pharm Res 27(11):2402-2413.
22. Kohn WD, Kay CM, Hodges RS. 1997. Salt effects on protein stability: Two-stranded alpha-helical coiled-coils containing inter- or intrahelical ion pairs. J Mol Biol 267(4):1039-1052.